- Home
- DTIL vs BTAI Comparison
DTIL vs BTAI Comparison
Compare DTIL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- BTAI
- Stock Information
- Founded
- DTIL 2006
- BTAI 2017
- Country
- DTIL United States
- BTAI United States
- Employees
- DTIL N/A
- BTAI N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- BTAI Health Care
- Exchange
- DTIL Nasdaq
- BTAI Nasdaq
- Market Cap
- DTIL 55.3M
- BTAI 48.3M
- IPO Year
- DTIL 2019
- BTAI 2018
- Fundamental
- Price
- DTIL $7.36
- BTAI $1.90
- Analyst Decision
- DTIL Strong Buy
- BTAI Buy
- Analyst Count
- DTIL 2
- BTAI 5
- Target Price
- DTIL $47.00
- BTAI $32.80
- AVG Volume (30 Days)
- DTIL 184.6K
- BTAI 950.0K
- Earning Date
- DTIL 11-03-2025
- BTAI 11-12-2025
- Dividend Yield
- DTIL N/A
- BTAI N/A
- EPS Growth
- DTIL N/A
- BTAI N/A
- EPS
- DTIL N/A
- BTAI N/A
- Revenue
- DTIL $1,261,000.00
- BTAI $868,000.00
- Revenue This Year
- DTIL N/A
- BTAI N/A
- Revenue Next Year
- DTIL $135.19
- BTAI $614.78
- P/E Ratio
- DTIL N/A
- BTAI N/A
- Revenue Growth
- DTIL N/A
- BTAI N/A
- 52 Week Low
- DTIL $3.61
- BTAI $1.17
- 52 Week High
- DTIL $8.96
- BTAI $12.16
- Technical
- Relative Strength Index (RSI)
- DTIL 58.34
- BTAI 31.26
- Support Level
- DTIL $6.63
- BTAI $2.14
- Resistance Level
- DTIL $8.77
- BTAI $2.46
- Average True Range (ATR)
- DTIL 0.70
- BTAI 0.15
- MACD
- DTIL 0.08
- BTAI -0.01
- Stochastic Oscillator
- DTIL 50.56
- BTAI 0.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.